ENCINITAS, Calif., August 7, 2026
Kiora Pharmaceuticals reported second quarter 2026 financial results while highlighting continued progress across its Phase 2 clinical pipeline for retinal diseases. The company advanced enrollment into the higher-dose cohort of the ABACUS-2 Phase 2 trial evaluating KIO-301 for late-stage retinitis pigmentosa (RP) and continued enrollment in the higher-dose cohort of the KLARITY Phase 2 trial of KIO-104 for macular edema associated with retinal inflammation. Kiora ended the quarter with approximately $16.8 million in cash and short-term investments, which, together with collaboration reimbursements and recent financing, is expected to fund operations into late 2028.
Phase 2 Programs Advance Across Retinal Disease Pipeline
Kiora continues to advance both of its lead ophthalmology programs through mid-stage clinical development. The ABACUS-2 study is evaluating KIO-301, a small-molecule molecular photoswitch designed to restore light sensitivity in patients with late-stage retinitis pigmentosa, regardless of the underlying genetic mutation. Enrollment has progressed into the 100 µg higher-dose cohort, with an independent safety review scheduled after treatment of the initial patients before broader enrollment continues. The company expects the last patient’s first visit during the first quarter of 2027, with topline data anticipated in the third quarter of 2027. Development costs for ABACUS-2 continue to be fully reimbursed through Kiora’s collaboration with Théa Open Innovation, which holds commercialization rights outside Asia.
Meanwhile, enrollment continues in the higher-dose cohort of the KLARITY Phase 2 trial evaluating KIO-104, a non-steroidal DHODH inhibitor administered by intravitreal injection for retinal inflammation and associated macular edema. The therapy has demonstrated a favorable safety profile to date, with initial clinical data expected in late 2026, which will guide future development across inflammatory retinal diseases.
Strategic Partnerships and Business Development Support Growth
Advertisement
Beyond clinical development, Kiora Pharmaceuticals continues evaluating potential strategic transactions aimed at expanding and diversifying its ophthalmology pipeline. Management indicated that completing a transaction by early 2027 could satisfy milestones tied to recently issued warrants, potentially unlocking additional financing. The company is also evaluating commercial partnership opportunities in South Korea for KIO-301, complementing its existing agreements with Théa Open Innovation and Senju Pharmaceutical covering key international markets. These regional collaborations could support a coordinated global Phase 3 registration strategy, subject to regulatory feedback.
Financial Position Extends Operating Runway into Late 2028
During the second quarter, Kiora secured a private placement worth up to $24 million in gross proceeds, including $5 million received upfront, with additional funding contingent upon milestone-based warrant exercises. The company reported research and development expenses of approximately $2.1 million before recognizing $1.3 million in reimbursable collaboration expenses, reflecting lower preclinical and manufacturing costs as programs advanced into clinical development. General and administrative expenses remained stable at approximately $1.4 million, while net loss totaled approximately $2.1 million, compared with $2.2 million during the same period in 2025. Supported by its cash position, collaboration reimbursements, and financing activities, Kiora expects to maintain operations through late 2028 while advancing both lead clinical programs.
Source:Kiora Pharmaceuticals press release
